Keyora Antarctic Krill Oil EP-1: The Marine Lipid Label Truth Test: Reconstructing Serving Size, Parent Oil, Structural Lipids, EPA-DHA-DPA Exposure, Quality Boundaries, and Goal-Matched Marine-Oil Choice

Background Marine-oil supplements are commonly compared through prominent front-label numbers such as “1,000 mg Krill Oil,” “2,000 mg Fish Oil,” or “1,200 mg Omega-3.” Although these quantities may all be expressed in milligrams, they do not necessarily describe the same analytical object. Total oil, total Omega-3 fatty acids, phospholipids, phosphatidylcholine, choline, eicosapentaenoic acid, docosahexaenoic acid, docosapentaenoic acid, and minor lipid-associated components can coexist within one marine-oil preparation while representing different levels of composition, structure, nutrient contribution, or active-fatty-acid exposure. Numerical similarity therefore does not establish chemical equivalence, nutritional equivalence, legitimate additivity, or clinical comparability. This problem is amplified by numerical anchoring. The largest visible number may become an intuitive proxy for potency before the consumer identifies what that number actually measures. A 1,000 mg total marine-oil value can consequently be interpreted as though it represented 1,000 mg of Omega-3, even when the quantified Omega-3 fraction is substantially smaller. The resulting error is not merely arithmetic. It can distort product comparison, apparent potency, nutrient exposure, research-dose matching, and the interpretation of formulation differences. Objective This article develops Keyora [The Marine Lipid Dose-Object Map] and Keyora [The Marine Lipid Label Truth Test] as complementary analytical frameworks for reconstructing marine-oil Supplement Facts before potency, efficacy, bioavailability, or product superiority is inferred. The objective is to replace front-label-number comparison with a serving-based hierarchy that distinguishes parent material, structural lipid objects, structural subobjects, nutrient contributions, active-fatty-acid totals, individual fatty-acid children, trace protective components, formulation characteristics, quality variables, and evidence-matching requirements. Keyora Antarctic Krill Oil EP-1 therefore addresses a foundational question: What does each number on a marine-oil label actually measure? It does not attempt to establish universal phospholipid superiority, disease treatment efficacy, direct tissue targeting, or the complete biological functions of EPA, DHA, DPA, phosphatidylcholine, choline, or Astaxanthin. Those questions require separate preparation-specific and endpoint-specific analyses. The Front-Label Number Illusion Keyora [The Front-Label Number Illusion] describes the interpretive error that occurs when numerical magnitude becomes a surrogate for dose identity. A value such as 1,000 mg appears precise and readily comparable. However, precision of quantity does not establish identity of the measured object. One thousand milligrams of total Krill Oil and one thousand milligrams of total Omega-3 represent fundamentally different exposures even though both are expressed using the same unit. The first rule of marine-lipid interpretation is therefore: identify the object before interpreting the number. This changes the basic comparison question from: “Which product has the largest number?” to: “What does the number measure, on what serving basis, and which biological or analytical object does it represent?” Serving Size as the Exposure Denominator Dose reconstruction begins with the serving rather than the front label. A capsule, declared serving, suggested-use instruction, and actual daily intake represent different exposure concepts. Without a fixed denominator, two apparently similar nutrient quantities may be compared on incompatible serving bases. For the current Keyora Antarctic Krill Oil formulation, the declared serving is one softgel. Every product-specific quantity evaluated in EP-1 is therefore reconstructed on this one-softgel basis. This establishes the label-controlled exposure unit but does not create an assumption regarding individualized daily use. A higher daily intake should only be calculated when an actual-use pattern is known and should not be inferred merely to reproduce a research dose or another manufacturer's serving recommendation. One-Softgel Exposure Reconstruction Within one declared softgel, the current Keyora Antarctic Krill Oil label identifies a 1,000 mg parent Antarctic Krill Oil matrix. Inside this parent matrix, the label separately declares: 572 mg total phospholipids; 495 mg phosphatidylcholine; 70 mg choline; 344 mg total Omega-3 fatty acids; 203 mg EPA; 118 mg DHA; 23 mg DPA; and 233 mcg Astaxanthin, equivalent to 0.233 mg. These values do not represent a flat collection of independent materials. The 1,000 mg value describes the complete parent marine-oil matrix rather than the Omega-3 dose. The 572 mg phospholipid value describes a structural lipid class. The 495 mg phosphatidylcholine value represents a quantified phospholipid subobject within the broader phospholipid amount and therefore should not be added independently to the 572 mg phospholipid total. The 70 mg choline declaration is a nutrient-contribution object. It is biologically related to phosphatidylcholine but is not equivalent to the complete molecular mass of phosphatidylcholine. The 344 mg total Omega-3 value represents the quantified marine Omega-3 parent object. EPA 203 mg, DHA 118 mg, and DPA 23 mg reconcile exactly to this total and therefore constitute children of the 344 mg Omega-3 value rather than three additional fatty-acid pools to be added after the total has already been counted. Astaxanthin requires unit normalization because 233 mcg equals 0.233 mg. Within this formulation it is interpreted as an embedded minor protection object rather than as an independent multi-milligram Astaxanthin intervention. The Non-Additive Marine Lipid Hierarchy Keyora [The Non-Additive Lipid Architecture] addresses a central arithmetic problem created by treating every declared amount as independent. A flat addition of the major label quantities produces an apparent total of 2,825.233 mg despite the declared parent Krill Oil matrix being 1,000 mg. This artificial contradiction emerges because the calculation simultaneously commits several classification errors. Parent totals are added to their children. Structural subclasses are added again to their parent structural classes. Nutrient contributions are treated as though they represented the mass of the complete molecule from which they arise. Total Omega-3 is added to EPA, DHA, and DPA despite those fatty acids already constituting the declared Omega-3 total. Different analytical dimensions of potentially overlapping lipid molecules are treated as though they represented physically separate pools. The correct response is therefore not to force all displayed milligrams into one grand total. It is to reconstruct their relationships. A more detailed label may represent greater compositional resolution rather than a larger physical quantity of independent material. Phospholipid Mass and Fatty-Acid Mass The non-additive framework becomes especially important when structural lipid measurements and fatty-acid measurements are interpreted together. A phospholipid quantity describes lipid-class mass. A fatty-acid quantity describes fatty-acyl mass. Some long-chain Omega-3 fatty acids can occur within phospholipid-containing molecular species in krill-oil preparations, meaning that phospholipid and fatty-acid measurements may represent different analytical dimensions of chemically overlapping material. The current label does not provide sufficient molecular-speciation data to assign every measured EPA, DHA, or DPA molecule to a specific phospholipid molecular species. Consequently, EP-1 does not infer expressions such as EPA-PC = 203 mg, DHA-PC = 118 mg, or DPA-PC = 23 mg. Exact molecular assignment requires direct lipid-speciation evidence. This boundary is essential because analytical distinction does not necessarily imply complete physical independence. Structure, Substrate, and Protection Keyora [The Structure-Substrate-Protection Architecture] explains why non-additive dose objects can nevertheless remain non-redundant. Total Krill Oil preserves information about the complete carrier environment. Phospholipids preserve information about structural lipid architecture. Phosphatidylcholine provides a more specific structural-lipid object. Choline preserves an independently declared nutrient contribution. Total Omega-3 establishes the measured marine-fatty-acid substrate pool. EPA, DHA, and DPA provide individual resolution within that total. Embedded Astaxanthin identifies a minor carotenoid-associated protective component. These measurements should not be collapsed merely because several describe related portions of the same marine-lipid matrix. Their value lies in preserving different information. The Complete Marine Omega-3 Disclosure The current one-softgel architecture declares total Omega-3 together with individual EPA, DHA, and DPA quantities. The arithmetic reconciliation: 203 mg EPA + 118 mg DHA + 23 mg DPA = 344 mg total Omega-3 provides an internal consistency check while increasing compositional transparency. Separate DPA disclosure is scientifically useful because it makes a fatty-acid object visible that would otherwise remain embedded within the aggregate Omega-3 total. However, disclosure itself is not an efficacy endpoint. The presence of 23 mg DPA does not establish vascular regeneration, platelet effects, reproductive benefit, anti-inflammatory efficacy, or superiority over another marine-oil product. Likewise, the presence of EPA and DHA does not allow higher-dose or differently formulated clinical studies to be transferred automatically to the exact current serving. From Dose Reconstruction to Evidence Matching Label interpretation and evidence interpretation are inseparable. Human studies evaluate defined preparations administered at defined exp